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Abstract
Background: Mesenchymal stem cells (MSCs) are one of the most promising candidates for the treatment of major
neurological disorders. Desirable therapeutic properties of MSCs include reparative and regenerative potential but,
despite their proven safety, the efficacy of MSCs remains controversial. Therefore, it is essential to optimise culture
protocols to enhance the therapeutic potential of the MSC secretome. Here we aimed to: assess the increase in
secretion of cytokines that may induce repair, regeneration, or immunomodulation when cultured in three dimensions;
study the effect of interleukin (IL)-1 priming on two- (2D) and three-dimensional (3D) cultures of MSC; and evaluate the
potential use of the modified secretome using microglial-MSC co-cultures.
Methods: We established a 3D spheroid culture of human MSCs, and compared the secretome in 2D and 3D cultures
under primed (IL-1) and unprimed conditions. BV2 microglial cells were stimulated with lipopolysaccharide (LPS) and
treated with spheroid conditioned media (CM) or were co-cultured with whole spheroids. Concentrations of secreted
cytokines were determined by enzyme-linked immunosorbent assay (ELISA). Protein arrays were used to further
evaluate the effect of IL-1 priming in 2D and 3D cultures.
Results: 3D culture of MSCs significantly increased secretion of the IL-1 receptor antagonist (IL-1Ra), vascular endothelial
growth factor (VEGF), and granulocyte-colony stimulating factor (G-CSF) compared with 2D culture, despite priming
treatments with IL-1 being more effective in 2D than in 3D. The addition of CM of 3D-MSCs reduced LPS-induced tumour
necrosis factor (TNF)-α secretion from BV2 cells, while the 3D spheroid co-cultured with the BV2 cells induced an increase
in IL-6, but had no effect on TNF-α release. Protein arrays indicated that priming treatments trigger a more
potent immune profile which is necessary to orchestrate an effective tissue repair. This effect was lost in 3D,
partly because of the overexpression of IL-6.
Conclusions: Increased secretion of anti-inflammatory markers occurs when MSCs are cultured in 3D, but this
specific secretome did not translate into anti-inflammatory effects on LPS-treated BV2 cells in co-culture. These data
highlight the importance of optimising priming treatments and culture conditions to maximise the therapeutic
potential of MSC spheroids.
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Background
Mesenchymal (stromal) stem cells (MSCs) are an attract-
ive candidate for use in therapies for the treatment of
major central nervous system (CNS) conditions such as
stroke, spinal cord injury, or amyotrophic lateral sclerosis
[1–5]. Key features of MSCs include their ability to sense
and migrate toward tumours [6] and inflamed, ischaemic,
or injured tissues [7]. Additionally, MSCs can cross the
blood-brain barrier [8] and secrete a wide variety of cyto-
kines and trophic mediators [2, 9, 10] that induce tissue
repair by activating endogenous protective mechanisms
[11, 12]. These effects are achieved with a low engraftment
rate and low rejection response from the host tissue,
which confers MSCs a uniquely high level of safety [1–3].
Nevertheless, since many aspects of MSC biology are still
unknown, efforts are being made to optimise culture con-
ditions to fully exploit their therapeutic potential.
Our previous study demonstrated that preconditioning
treatments of MSCs in two-dimensional (2D) culture
with interleukin (IL)-1 enhances the secretion of pro-
trophic molecules, such as granulocyte-colony stimulat-
ing factor (G-CSF) [13]. Furthermore, conditioned media
(CM) from IL-1-primed MSCs modified the inflamma-
tory response of microglial cells after lipopolysaccharide
(LPS) stimulation, as demonstrated by a reduced secre-
tion of inflammatory and pro-apoptotic molecules (such
as IL-6 and G-CSF) and tumour necrosis factor (TNF)-
α. This confirmed the use of 2D-MSCs as modulators of
inflammation, as previously reported [10, 14]. Following
on from our previous study, and with the aim of
inducing a greater change in the MSC secretome, we
assessed the effect of culturing cells in three dimensions
and the effect of priming treatments in these MSC
spheroids. MSCs express different secretomes when
cultured in three dimensions, such as increased wound
healing features and angiogenesis [15–19] and enhanced
anti-inflammatory potential when grown under three-
dimensional (3D) conditions [18, 20]. Three-dimensional
cultures provide a more physiological environment for
cells, and trigger enhanced expression of other desirable
phenotypes, such as improved MSC stemness and in-
creased survival post-transplantation [18]. Spheroid for-
mation can be considered as an optimisation of MSC
culture to enhance their therapeutic potential [17, 18, 21],
and MSC spheroid treatments have already been tested
with moderate success in bone regeneration [22, 23] and
in inflammatory and ischaemic models, such as colitis and
stroke [19, 24].
Here we show for the first time that, when cultured
under 3D conditions, MSCs show marked increased se-
cretion of the IL-1 receptor antagonist (IL-1Ra), vascular
endothelial growth factor (VEGF), and G-CSF, the latter
being further increased by priming with IL-1. This en-
hanced anti-inflammatory phenotype did not, however,
translate into an anti-inflammatory effect of MSCs on
LPS-mediated cytokine release in BV2 cells in co-cul-
ture. Cytokine arrays revealed that priming of 2D cells
induced an overexpression of proteins related to inflam-
matory and immune responses, but not in 3D cultures.
Primed 3D-MSCs not only modified their secretome and
secreted some anti-inflammatory cytokines, but also in-
duced an increase in IL-6, and a decrease in IL-10 and
CCL22. On the other hand, priming of spheroids in-
duced an increase in the secretion of matrix metallopro-
teinases (MMPs), key molecules for further tissue repair
and angiogenesis. These findings highlight the import-
ance of optimising culture methods and priming proto-
cols to maximise the therapeutic potential of MSCs.
Methods
Cell cultures
Mesenchymal stem cells (MSCs)
Human bone marrow-derived MSCs were purchased
from 3H Biomedical (Sweden). Cells (harvested from a
22-week fetus) were differentiated into osteocytes or adi-
pocytes using commercial kits (Millipore, UK) and char-
acterised by the presence or absence of specific surface
markers (CD73, CD90, CD105, CD34, CD11b, CD19,
CD45, and HLA-DR), the minimal criteria for identifying
MSCs [25].
Culture flasks (Corning, UK) were coated with 0.1%
gelatin in phosphate-buffered saline (PBS) overnight at
37 °C, and washed with PBS prior to cell seeding. Cells
were expanded and cultured in MesenPRO RS® medium
(Invitrogen, UK) supplemented with 1% penicillin/
streptomycin and 2 mM glutamine (Sigma-Aldrich, UK).
Medium was changed every 4–5 days until cultures
reached 70–80% confluency. Cells were then detached
using 0.5% trypsin-EDTA (Sigma-Aldrich, UK), counted,
and split into different culture flasks, and further cul-
tured as described above. Cells used for experiments
were obtained from passage 5–6 and seeded at 13,000
cells/cm2 (for the 2D cultures),
3D spheroid formation
MSCs were harvested at passage 5–6 using 0.5% trypsin-
EDTA, and sub-cultured in low-binding plates (Nunc
International, Japan) using 50 μl MesenPRO RS®. The
number of cells used in each spheroid (20,000 cells) was
slightly higher than that used in 2D cultures, since not
all cells formed spheroids. Spheroids were considered
fully formed after 5 days in vitro [26]. Images of spher-
oids were taken with an inverted microscope (Olympus
CK X31), using a Moticam 2300 camera coupled to
Motic Images Plus 2.0 ML software at different time
points to monitor spheroid formation. Spheroid size was
estimated from the calculation of area and perimeter of
the picture showing maximum sectional area (Fig. 1d).
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All clusters of cells with an area inferior to 0.15 mm2
were not considered spheroids and were therefore
excluded in the measurements. The area was measured
using ImageJ software (U.S. National Institutes of
Health, Bethesda, Maryland, USA), and 25–30 spheroids
for each treatment were included in the measurement
(total n = 131 spheroids).
To confirm their physical structure, spheroids were
fixed in 4% paraformaldehyde, cryopreserved with 30%
glucose in phosphate buffer, and stained with haema-
toxylin and eosin (Fig. 1b) before being sectioned at
20 μm for DAPI staining (Fig. 1c).
Microglial cells (BV2s)
BV2 cells, an immortalised murine microglial cell line,
were purchased from ATCC (UK) and cultured in
RPMI-1640 medium (Sigma-Aldrich, UK) supplemented
with 10% fetal bovine serum (FBS; Invitrogen, UK) and
1% penicillin/streptomycin (Sigma-Aldrich, UK) until
70–80% confluent. Cells were detached with 0.5%
trypsin-EDTA (Sigma-Aldrich, UK), counted, and seeded
at a density of 13,000 cells/cm2.
Cell treatments
Priming experiments in 2D versus 3D
Cells were treated (24 h after plating for 2D cultures or
5 days in vitro after plating for 3D cultures) with human
recombinant IL-1α, IL-1β, TNF-α, or interferon (IFN)-γ
at a final concentration of 10 ng/ml (all from R&D
Systems, UK). After 24 h, supernatants were collected
and assayed for key human cytokines. As spheroid for-
mation requires a small amount of media, cytokine con-
centrations from 2D and 3D cultures were normalised
by the volume of supernatant collected from the wells at
the end of the experiment (~50 μl in 3D, ~500 μl in 2D).
The initial number of cells was also used as a normalisa-
tion factor. Three independent cultures were included,
with at least three technical replicates per condition.
Co-culture experiments: BV2 and 3D conditioned media (CM)
MSC spheroids cultured for 5 days in vitro were treated
for 2 h with 10 ng/ml IL-1α or IL-1β, and then washed
twice with PBS and placed back in the low-binding plate
with fresh media. Priming time was reduced to 2 h as
shorter times were sufficient to induce changes in
cytokine secretion (data not shown). Supernatants were
collected 24 h later for further analysis of secreted cyto-
kines by enzyme-linked immunosorbent assay (ELISA).
In parallel, 25,000 BV2 cells were seeded, cultured for
24 h, and then treated for 2 h with bacterial LPS (1 μg/ml,
serotype E. coli 0127:B8, Sigma-Aldrich, UK). After LPS
treatment, cells were washed twice with PBS and the
spheroid-CM was added to BV2 cells, diluted 1/10 in
MesenPRO RS®. Supernatants were collected 24 h later
and further analysed for the presence of mouse and hu-
man cytokines by ELISA. Final volumes in the wells were
matched in each condition; therefore, no normalisation
was carried out in this experiment. Three independent
Fig. 1 Formation and measurements of spheroids. a Scheme of the formation of spheroids, with representative images at different times of growth. b
Haematoxylin and eosin staining of a 20-μm section of a spheroid, in a bright field image. c Immunostaining of the same section using DAPI, indicating
a compact cellular structure. d Spheroids were measured at different time points by measuring the maximum sectional area, indicated in the image as
a dashed line. e Areas of main spheroids (mean + SEM) were larger at early time points and decreased with time, indicating the compaction of the
spheroid. Scale bars = 500 μm in a, 200 μm in b–d. ****p < 0.001. P passage
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cultures were included, with at least three technical repli-
cates per condition.
Co-culture experiments: BV2 and whole 3D spheroids
MSCs and BV2 cells were seeded and treated as de-
scribed; however, after the priming treatment with IL-1,
MSC spheroids were washed twice with PBS and placed
into a transwell insert (0.4-μm pore size; Greiner Bio
One, UK) that had been previously equilibrated in RPMI
media overnight. Inserts were placed on top of BV2 cells
for 24 h, after which supernatants were collected and
further analysed for the presence of mouse and human
cytokines by ELISA. Another set of spheroids was
primed (or left unprimed) as previously described and
maintained in inserts in the absence of BV2 cells. Final
volumes in the wells were matched in each condition;
therefore, no normalisation was carried out in this
experiment. Three independent cultures were included,
with at least three technical replicates per condition.
ELISA
The levels of VEGF, G-CSF, IL-6, TNF-α, and IL-10 were
quantified by ELISA using mouse (m) or human (h) Duo-
Set® kits (R&D Systems, UK) according to the manufac-
turer’s instructions. IL-1Ra levels were measured using an
ELISA kit from Peprotech (UK) combined with external
standards prepared using recombinant human IL-1Ra
(National Institute for Biological Standards and Controls,
NIBSC, UK). For each assay, protein levels were calculated
against a four-parameter logistic (4-PL) curve fit. Quantifi-
cation limits were ~30 pg/ml for all the cytokines mea-
sured (except TNF-α, ~60 pg/ml), and no statistical
analyses were carried out for values below this limit.
Membrane arrays
A human cytokine antibody array (Abcam, UK) was used
to compare the secretion of cytokines secreted by MSCs
in 2D and 3D, under primed and unprimed conditions.
Supernatants from 2D and 3D were concentrated and
diluted (respectively) up to four times, so that results
from the arrays were directly comparable.
A human MMP array was used to assess the differ-
ences in secretion of tissue remodelling proteins in 3D
cultures. Supernatants from at least two independent
experiments were pooled to reach 1 ml of supernatant
required for the membrane array.
For both arrays, densitometry data were obtained
using ImageJ software, and normalised against the un-
treated values; therefore, the priming effect could be eas-
ily observable in 2D and 3D cultures. A PANTHER
over-representation test [27] including all the analysed
cytokines was performed against a human protein data-
base to detect the main biological processes related to
the overexpressed proteins.
Statistical analysis
Cytokine concentrations are expressed as mean ± stand-
ard error of the mean (SEM). Data presentation and
analysis was performed using GraphPad Prism software
version 6.04 for Windows (California, USA). All differ-
ences were assessed by one-way analysis of variance
(ANOVA). Data from 2D–3D comparisons were ana-
lysed after applying a linear logarithmic transformation.
Holm Sidak post-hoc tests were performed if statistical
significance was achieved (p < 0.05). Densitometry data
were normalised versus the untreated conditions and
differences were assessed by two-way ANOVA. Sidak’s
multiple comparison tests were applied if statistical
significance was achieved (p < 0.05).
Results
Characterization of MSCs
Cells were positively characterised as MSCs for their abil-
ity to differentiate into adipocytes and osteocytes and by
the presence of CD90, CD105, and CD73 surface markers
and the absence of CD34, CD11b, CD45, CD19, and
HLA-DR, as stated by the International Society for Cellu-
lar Therapy [25] and as we have previously published [13].
Assessment of spheroid formation
All wells containing cells generated at least one spher-
oid. At day 1, spheroids were visible in all wells (Fig. 1a)
sometimes surrounded by individual cells. At day 4,
most of the cells had been incorporated into spheroids,
and at day 6 the number of individual cells surrounding
the spheroids was markedly reduced. Spheroids were
visualised as compact cellular structures (Fig. 1b, c), and
were significantly smaller (measured as indicated in
Fig. 1d) at day 6 compared to day 4 (Fig. 1e), indicating
compaction as previously described [20, 28].
MSCs display increased secretion of cytokines in 3D
cultures
The secretion of different cytokines was measured in
supernatants of MSCs cultured in 2D and 3D. Cells in
2D secreted low concentrations of G-CSF, only detect-
able after priming treatment with IL-1 (Fig. 2a). Secre-
tion of G-CSF was significantly increased by 20-fold in
3D cultures (up to ~2 fg/cell in untreated conditions; p
< 0.05). Priming spheroids with IL-1α and IL-1β in-
creased secretion of G-CSF sixfold (p < 0.0001, 2D versus
3D; p < 0.01, IL-1α versus untreated; p < 0.05, IL-1β
versus untreated). TNF-α and IFN-γ treatment had no
effect on G-CSF secretion in 2D or 3D cultured cells.
Secretion of IL-1Ra from 2D cultured MSCs was un-
affected by priming (Fig. 2b), but was significantly in-
creased when cultured in 3D cultures (18-fold increase
on average; p < 0.001, 2D versus 3D). Priming had no ef-
fect on IL-1Ra secretion in 3D cultures. VEGF secretion
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was strongly augmented in spheroids compared to 2D
conditions (25-fold increase; p < 0.001; Fig. 2c). None of
the priming treatments changed the secretion of VEGF,
whether cells were in 2D or 3D culture. Secretion of IL-
10 under 2D conditions was very low and not detectable
when in 3D, and there was no effect of any priming
treatment (Fig. 2d).
Modulation of BV2 inflammatory responses
Given the enhanced anti-inflammatory phenotype, we
hypothesised that the increased secretion of cytokines
induced by the 3D culture of MSCs could exert anti-
inflammatory effects on LPS-stimulated BV2s. Since only IL-
1α and IL-1β priming induced enhanced secretion of G-CSF,
only these cytokines were tested in further experiments.
Treatment of BV2 with conditioned media from MSC
spheroids
BV2 cells previously treated with LPS were treated with
CM from primed spheroids (alongside appropriate controls,
as shown in Fig. 3a). Priming of MSC spheroids induced a
significant increase in hIL-6 secretion (Fig. 3b; p < 0.05) and
hG-CSF (Fig. 3d; p < 0.05), but not hTNF-α (Fig. 3c), as
measured in the 3D-CM.
When 3D-CM was added to BV2 cells, the concentra-
tions of the same human cytokines were reduced after
24 h, indicating uptake or degradation by the BV2 cells.
Human IL-6 was undetectable in untreated conditions,
but was significantly increased after IL-1α and IL-1β
priming (Fig. 3e; p < 0.01). The response of hG-CSF was
similar to hIL-6 (Fig. 3g; p < 0.01, IL-1α/β versus un-
treated; p < 0.0001, IL-1α versus IL-1β). Levels of hTNF-
α were below the quantification limit under all condi-
tions (Fig. 3f, dashed line).
Finally, quantification of murine molecules in the
supernatant showed a trend towards an increase in mIL-
6 under LPS-treated conditions (Fig. 3h). Secretion of
mTNF-α from BV2s (Fig. 3i) increased following LPS
stimulation (greater than fourfold increase), and this was
significantly reduced by treatment with CM from IL-1α-
Fig. 2 Secretion of different trophic factors and inflammatory mediators in two-dimensional (2D) and three-dimensional (3D) cultures. Cells cultured in
2D and 3D were primed with Interleukin (IL)-1α, IL-1β, tumour necrosis factor (TNF)-α, or interferon (IFN)-γ. ELISA measurements (normalized to the
initial number of cells and the final volume in the wells after the treatments) indicate that cells in 3D secrete more granulocyte-colony stimulating
factor (GCSF) (a), IL-1 receptor antagonist (IL-1Ra) (b), and vascular endothelial growth factor (VEGF) (c), but not IL-10 (d). Priming treatments were only
effective in inducing the secretion of GCSF. *p < 0.05, ***p < 0.001, versus 2D; +p < 0.05, ++p < 0.01, versus untreated. nd not detectable
Redondo-Castro et al. Stem Cell Research & Therapy  (2018) 9:11 Page 5 of 11
and IL-1β-primed spheroids (p < 0.05 and p < 0.01,
respectively). Levels of mG-CSF (Fig. 3j) increased more
than 100-fold with the LPS treatment (p < 0.01), and
were not altered by CM treatment.
Co-culture of BV2 and MSC spheroids
To maximise the effect seen with the spheroid CM on
the BV2 response to LPS, co-culture experiments with
whole spheroids were conducted (including appropriate
control experimental conditions, as depicted in Fig. 4a).
Measurements of CM from spheroids placed in inserts
for 24 h showed that priming treatments with IL-1 in-
duced an increase in hIL-6, especially after IL-1β (Fig. 4b;
p < 0.05), but not for hTNF-α which remained undetect-
able (Fig. 4c). Human G-CSF secretion was not detect-
able in untreated conditions, but significantly increased
after IL-1α and IL-1β priming (Fig. 4d; p < 0.05 and p <
0.01, respectively). These results demonstrate a similar
response to priming as in the previous experiment
(Fig. 3b–d); however, lower concentrations of IL-6 and
TNF-α were observed here, indicating that contact of
the spheroid with the insert reduces the secretion of
these cytokines from MSCs.
The concentration of these cytokines was conse-
quently reduced when measured in the supernatant of
the co-culture, indicating the uptake or break-up of
human proteins by murine cells (Fig. 4e–g). Levels of IL-
6 were significantly increased because of the priming
(Fig. 4e; p < 0.05 and p < 0.01, versus untreated), as well
as levels of G-CSF, especially after IL-1β treatment
(Fig. 4g; at least p < 0.05, versus untreated,). TNF-α
remained undetectable (Fig. 4f ).
Treatment of BV2s with LPS induced a significant
increase in the secretion of mIL-6 (p < 0.001), and co-
culture with spheroids induced a higher secretion of IL-6
(statistically significant only in the case of IL-1β-primed
spheroids; Fig. 4h; p < 0.001, versus LPS). Secretion of
mTNF-α from BV2s was significantly increased following
Fig. 3 Treatment of BV2 using conditioned media (CM) from spheroids. a Mesenchymal stem cells (MSCs) were expanded and cultured in 3D to
form spheroids. After interleukin (IL)-1 priming, conditioned media from spheroids were collected and added to BV2 cells previously treated with
lipopolysaccharide (LPS). Human (h) and murine (m) cytokines were analysed from supernatants 24 h later. Measurements of human cytokines in
the conditioned media (b–d) and in the supernatant from treated BV2s (e–g). Murine cytokines were also analysed from the supernatants (h–j).
Results indicate that priming spheroids increased the secretion of IL-6 and granulocyte-colony stimulating factor (G-CSF). Analysis of the supernatant of
the co-culture revealed a significant decrease in murine tumour necrosis factor (mTNF)-α after treatment with CM from primed spheroids. Dashed lines
in c and f indicate the quantification limit for TNF-α ELISA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. nd not detectable, P passage, PBS
phosphate-buffered saline, unt untreated
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LPS stimulation (Fig. 4i; p < 0.001). Spheroid co-culture
did not induce any change in TNF-α secretion. Similarly,
mG-CSF significantly increased under all LPS-treated
conditions (Fig. 4j; p < 0.01). The addition of primed
spheroids had no effect on the secretion of mG-CSF.
IL-1 priming induced the secretion of cytokines related to
immune and inflammatory responses
To evaluate possible key mediators involved in the
effects seen in the BV2 culture, a protein array was per-
formed including a wide variety of cytokines and trophic
factors. Once data were normalised against the untreated
condition, two-way ANOVA revealed that the effect of
different culture conditions (2D or 3D) had a major ef-
fect (p < 0.05) on the change in protein secretion, rather
than the priming treatments. Despite every treatment
and condition inducing a unique combination of pro-
teins being differentially secreted, only a few cytokines
appeared upregulated under all the conditions (greater
than twofold increase), such as macrophage-colony
stimulating factor (M-CSF), TNF-β, CCL22, or growth-
regulated protein alpha (GRO-α) (Fig. 5). The over-
representation test [27] performed with these proteins
indicated that these proteins were related to the orches-
tration of inflammatory and immune responses, affecting
the function of other cell types such as macrophages or
monocytes and inducing a higher response to cytokine
signalling processes. More precisely, regulation of recep-
tor activity, cytokine signalling, and inflammatory
response were some of the terms that presented the
smaller p values (p < 10–10; Fig. 5 and Tables 1 and 2),
confirming the involvement of these over-expressed
cytokines in the cited biological processes. Despite all
these processes also seeming to be over-represented in
the 3D secretomes, the increase in the expression of
these cytokines was higher under the 2D conditions.
IL-1β regulates expression of MMPs in 3D-MSCs
Conditioned media from 3D-MSCs (primed or un-
primed) were used to analyse the expression of tissue
Fig. 4 Treatment of BV2 using spheroids in inserts. a Mesenchymal stem cells (MSCs) were expanded and cultured in 3D to form spheroids, primed
with interleukin (IL)-1 and co-cultured in inserts with BV2 cells previously treated with lipopolysaccharide (LPS). Measurements of human (h) cytokines
on the conditioned media added to the BV2s (b–d), and in the conditioned media obtained from cells after 24 h in the inserts (e–g). Murine (m)
cytokines were also analysed from the co-culture supernatants (h–j). Analysis of the supernatant of the co-culture revealed a significant increase in
mIL-6 after adding conditioned media (CM) from IL-1β-primed spheroids. Dashed lines in c and f indicate the quantification limit for tumour necrosis
factor (TNF)-α ELISA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. G-CSF granulocyte-colony stimulating factor, nd not detectable, P passage, PBS
phosphate-buffered saline, unt untreated
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remodelling proteins. MMP protein arrays showed
increases in MMP-2, MMP-10, MMP-13, and tissue in-
hibitor of metalloproteinases (TIMP-1) in IL-1α- and IL-
1β-primed MSC spheroids (Fig. 6). MMP-13 and TIMP-
1 showed the greatest increases, especially after IL-1β
priming.
Discussion
Modulation of the secretome of MSCs is an essential
step towards achievement of the full therapeutic poten-
tial of MSCs. Despite the enhancement in the secretion
of cytokines and trophic factors that has been previously
described in 3D-MSCs [18, 29, 30], there are only a few
studies in vitro that tested this potential in macrophages
[20] and cancer cells [21]. The efficacy of 3D-MSCs in
vivo has not been fully proven, with just a few studies
reporting their pro-angiogenic effects [15, 16], and only
a couple of secretome modulation approaches have
already been proven to be successful in in-vivo models
of cerebral ischaemia [17, 19].
Here, we show that 3D culture modifies the secretome
of human MSCs, leading to an enhanced secretion of G-
CSF and IL-1Ra, key molecules involved in tissue repair
and modulation of inflammation. As we have recently
demonstrated that CM from 2D-MSCs exerts potent
anti-inflammatory effects on LPS-treated BV2 microglial
cell cultures [13], in this present study we hypothesised
that an enhanced anti-inflammatory phenotype of 3D-
MSCs could exert more potent anti-inflammatory effects
on LPS-treated BV2 cells. Specifically, we tested whether
the secretion of inflammation markers in BV2 cells
could be modified by treating them with 3D-CM or co-
culturing with whole MSC spheroids placed in inserts.
Only IL-1-primed spheroid CM resulted in decreased
TNF-α secretion from LPS-treated BV2s, indicating the
importance of priming treatments for modulating
responses to inflammation in other cell types. This effect
was lost when the whole spheroids were co-cultured
with BV2s, as TNF-α secretion was not reduced and an
increase in IL-6 was observed instead, particularly in the
presence of IL-1β-primed spheroids.
To explain these results, more cytokines were included
in a secretome analysis, and it was revealed that IL-1
priming also increased the secretion of several proteins
involved in the inflammatory and immune response and
the recruitment of immune cells (including GRO-α,
MCSF, CCL22, and CCL7), and that this increase was
more marked in 2D cells than in spheroids. This effect is
achieved by secreting a wide variety of cytokines [9] that
would act in other cells, mostly immune cells [31, 32],
but not necessarily microglia (or BV2 cells in this case).
Fig. 5 Heat map showing the cytokine concentrations secreted by
MSCs cultured in two-dimensions (2D) and three dimensions (3D)
after priming with IL-1α or IL-1β. Cytokines were analysed from the
conditioned media of MSCs cultured in 2D and 3D, under untreated
or primed conditions (IL-1α or IL-1β). Colours are assigned according
to the relative scale of expression, ranging from 0 to 10, and
representing fold-increase change versus the untreated condition
Table 1 Over-represented biological processes after interleukin
(IL)-1 priming in two-dimensional and three-dimensional
cultures
Biological process p value
Regulation of receptor activity 5.93E-14
Cytokine-mediated signalling pathway 9.27E-14
Inflammatory response 2.64E-12
Cellular response to cytokine stimulus 5.19E-12
Response to cytokine 1.65E-11
Cell chemotaxis 4.83E-11
List of the biological processes that were over-represented in the analysis of the
cytokine array, and their corresponding p value. The list of proteins analysed were
compared against a human database using a PANTHER over-representation test
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In other words, IL-1 priming might be enhancing the
ability of MSCs to induce a microenvironment that per-
mits the repair of injured and inflamed tissues. Despite
the upregulation of some proteins under both 2D and
3D conditions, the magnitude of the change was smaller
in 3D conditions. This attenuated effect of IL-1 priming
in 3D-MSCs may be due to the fact that the IL-1 signal-
ling cascade is already upregulated due to the spheroid
formation process itself [28], or to the fact that only the
cells on the outer surface of the spheroids are exposed
to these treatments. Besides, 3D-MSCs not only modi-
fied their secretome towards the release of more anti-
inflammatory mediators but also induced other changes
that may be detrimental in our co-culture model, such
as the increase in IL-6 and the decrease in IL-10 and
CCL22. We cannot discard here the dual role of certain
cytokines such as IL-6 or G-CSF [33–35].
We also assessed the secretion of matrix metallopro-
teinases (MMPs) involved in tissue remodelling and
repair, and which are believed to also have a dual role in
neurological conditions such as stroke. While they medi-
ate tissue injury in the acute phase of ischaemic stroke,
their actions may well be beneficial during the recovery
phase [36, 37]. In fact, MMP-9 and MMP-13 are
involved in lesion growth [37], and MMP9 is also associ-
ated with increases in lesion volume and neurological
deficits [38]. Priming of 3D-MSC spheroids leads to
increased levels of MMP-13, particularly after treatment
with IL-1β, and so may not have a therapeutic benefit if
given in the acute phase after stroke. On the other hand,
MMPs may have a valuable role in the recovery phase by
contributing to neurovascular remodelling [36, 39] and
by increasing of the bioavailability of VEGF [40]. Fur-
thermore, TIMP-1 has anti-apoptotic effects and may be
neuroprotective when given after stroke [41, 42].
Despite being promising in preclinical and in-vitro
preparations, MSC spheroids are no more effective than
their 2D counterparts [43, 44], confirmed by the fact
that there are few published reports showing positive
effects of MSC spheroids.
Nevertheless, MSC spheroids still represent a potential
as a therapeutic option since they become less entrapped
in the lungs and the capillaries when transplanted, and
thus can survive for longer [28, 45], and they offer the
chance of obtaining a unique combination of anti-
inflammatory and immunomodulatory factors [31]. How-
ever, despite presenting all these desirable characteristics,
the efficacy of spheroid MSCs still remains unproven.
Indeed, treatment with CM (instead of the whole spher-
oid) may be a more effective treatment, maintaining anti-
inflammatory and immune modulatory effects but mitigat-
ing the risks associated with a cell transplantation. Future
studies should focus on assessing the efficacy of these
treatments on in-vivo models of inflammation.
Table 2 Main cytokines upregulated after interleukin (IL)-1 priming in two-dimensional and three-dimensional mesenchymal
stem cells
Cytokine Name Function
MCSF Macrophage colony-stimulating factor Induces haematopoietic stem cells to differentiate into
macrophages. Promotes release of pro-inflammatory
cytokines to induce immune and inflammatory responses
TNF-β Tumour necrosis factor β or lymphotoxin-α Regulation of cell survival. Immunostimulatory mediator
CCL7/MCP3 Chemokine (C-C motif) ligand 7 or monocyte-
chemotactic protein 3
Monocyte attractant and regulator of macrophage functions
Gro-α CXCL1 Growth-regulated protein alpha Cell proliferation, involved in inflammatory and immune responses
CCL22 C-C motif chemokine 22 Attractant of immune cells to inflammatory sites
TNF-α Tumour necrosis factor α Involved in inflammatory and immune responses
CK B 8-1 or CCL23 C-C motif chemokine 23 Chemotactic activity for monocytes, resting T lymphocytes,
and neutrophils. Involved in responses to IL-1
IL-6 Interleukin-6 Inducer of acute phase response. Dual effects as pro- and
anti-inflammatory molecules
IL-10 Interleukin-10 Anti-inflammatory. Inhibits the synthesis of interferon (IFN)-γ,
IL-2, IL-3, TNF, and GM-CSF in macrophages
IL-8 Interleukin-8 Chemotactic for neutrophils and T cells
MIG/CXCL9 Monokine induced by gamma interferon/C-X-C
motif chemokine 9
Affects activation state of cells involved in immune
and inflammatory responses
G-CSF Granulocyte colony-stimulating factor Anti-apoptotic, involved in immune and inflammatory
responses
Names of the main cytokines modified by priming treatments, with some of their main functions described. These cytokines were the most upregulated after
priming with IL-1. All function terms have been obtained from the UniProt database
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However, it is crucial to continue to increase our
knowledge of the basic biology of MSCs, as priming
treatments and changes in culture conditions can
have great effects on the MSC secretome [13, 31, 45]
and may increase their efficacy in the treatment of
CNS conditions.
Conclusions
Here, we describe how MSCs secrete more anti-
inflammatory, pro-trophic, and pro-angiogenic factors
when they are cultured under 3D conditions. However,
this is not translated into a reduction in inflammatory
responses in in-vitro cultures of BV2 cells, and the
secretome analysis indicates that MSCs have a potential
role as great orchestrators of inflammatory and immune
responses by acting on other cell types, and that this
phenotype can be modulated by IL-1 priming, especially
in MSCs cultured under 2D conditions. These results
highlight the importance of improving our understand-
ing of MSC biology under different culture and priming
conditions to optimise their potential therapeutic use.
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Fig. 6 Expression of tissue remodelling molecules in 3D-MSC-
conditioned media. Several matrix metalloproteinases (MMPs) and
tissue inhibitors of metalloproteinases (TIMPs) were analysed from
the conditioned media of 3D-MSC cultures (untreated or primed
with interleukin (IL)-1α or IL-1β). Expression changes are expressed
as fold-increase versus the untreated values and coloured according
to the relative scale of expression ranging from 0 to 10
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